U.S. patent application number 10/927960 was filed with the patent office on 2005-07-14 for method and apparatus for in vivo surveillance of circulating biological components.
Invention is credited to Hoon, David, Shaolian, Samuel, Taback, Bret.
Application Number | 20050153309 10/927960 |
Document ID | / |
Family ID | 34743010 |
Filed Date | 2005-07-14 |
United States Patent
Application |
20050153309 |
Kind Code |
A1 |
Hoon, David ; et
al. |
July 14, 2005 |
Method and apparatus for in vivo surveillance of circulating
biological components
Abstract
The invention relates generally to in vivo collection of
circulating molecules, tumor cells and other biological markers
using a collecting probe. The probe is configured for placement
within a living organism for an extended period of time to provide
sufficient yield of biological marker for analysis.
Inventors: |
Hoon, David; (Los Angeles,
CA) ; Taback, Bret; (Santa Monica, CA) ;
Shaolian, Samuel; (Newport Beach, CA) |
Correspondence
Address: |
KNOBBE MARTENS OLSON & BEAR LLP
2040 MAIN STREET
FOURTEENTH FLOOR
IRVINE
CA
92614
US
|
Family ID: |
34743010 |
Appl. No.: |
10/927960 |
Filed: |
August 27, 2004 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
60531928 |
Dec 22, 2003 |
|
|
|
Current U.S.
Class: |
435/6.16 ;
435/287.2; 435/7.92 |
Current CPC
Class: |
A61B 5/14546 20130101;
B82Y 30/00 20130101; A61B 5/14735 20130101; A61B 5/6862 20130101;
A61B 2562/0285 20130101; G01N 33/54366 20130101; A61B 5/6851
20130101 |
Class at
Publication: |
435/006 ;
435/007.92; 435/287.2 |
International
Class: |
C12Q 001/68; G01N
033/53; G01N 033/537; G01N 033/543; C12M 001/34 |
Claims
What is claimed is:
1. A biological surveillance probe for detecting disease,
comprising an elongate body having a proximal end and a distal end;
a binding surface attached to the elongate body, wherein the
binding surface has a microconfiguration for an increased surface
area; and at least one binding partner attached to the binding
surface to bind at least one complementary target.
2. The probe of claim 1, wherein the binding surface is a
microporous surface.
3. The probe of claim 1, wherein the binding surface has at least
one laser-drilled hole.
4. The probe of claim 1, wherein the binding surface has been
configured by vapor deposition.
5. The probe of claim 1, wherein the binding surface has been
configured by physical vapor deposition.
6. The probe of claim 19, wherein the binding surface has been
configured by chemical vapor deposition.
7. The probe of claim 1, wherein the binding surface has been
configured by sputtering.
8. The probe of claim 7, wherein the binding surface has been
configured by reactive sputtering.
9. The probe of claim 1, wherein the binding surface has been
configured by sintering.
10. The probe of claim 1, wherein the binding surface has been
configured by vacuum deposition.
11. The probe of claim 2, wherein the binding surface comprises a
material selected from a group comprising a microporous polymer,
nanotube, metal, non-metal, ceramic or combination thereof.
12. The probe of claim 1, wherein the elongate body is a catheter
body.
13. The probe of claim 1, wherein the elongate body is a stent
support.
14. The probe of claim 13, wherein the binding surface is polymeric
jacket.
15. The probe of claim 1, further comprising at least one optically
sensitive dye engaged to the binding surface.
16. The probe of claim 1, further comprising a fibrin-deposition
resistant component.
17. The probe of claim 1, further comprising at least one
anti-thrombotic agent engaged to the binding surface.
18. The probe of claim 1, further comprising at least one
antimicrobial agent engaged to the binding surface.
19. The probe of claim 1, further comprising an atraumatic tip
attached to the distal end of the elongate body.
20. A method for collecting biological markers, comprising the
steps of: providing a collecting probe comprising a microconfigured
binding surface and at least one binding agent affixed to the
binding surface for binding a marker; positioning at least a
portion of the probe in an anatomical structure of a living
organism; maintaining the probe in a general position for a
specified period of time; and removing the probe from the living
organism.
21. The method of claim 20, further comprising: binding at least
one marker at a first point in time; and binding at least one
marker at a second point in time.
22. The method of claim 20, further comprising: binding at least
one marker at about a first peak in marker concentration; and
binding at least the biological marker at about a second peak in
marker concentration.
23. The method of claim 20, further comprising analyzing the probe
for markers bound to the binding agent.
24. The method of claim 23, wherein the analyzing step is performed
ex vivo.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The present application claims priority under 35 U.S.C.
.sctn.119(e) to U.S. Provisional Application No. 60/531,928 filed
on Dec. 22, 2003, the disclosure of which is incorporated by
reference herein in its entirety.
BACKGROUND OF THE INVENTION
[0002] 1. Field of the Invention
[0003] This invention relates generally to devices and methods for
collecting and/or detecting biological components in vivo over a
period of time. The detection and/or analysis of the biological
components collected by the devices may be performed in vivo or ex
vivo.
[0004] 2. Description of the Related Art
[0005] Cancer is one of the leading causes of disease, being
responsible for 563,700 deaths in the United States each year
(Jemal A et al., Cancer statistics, 2004, CA Cancer J. Clin. 2004
January-February; 54(1): 8-29). For example, breast cancer is the
most common form of malignant disease among women in Western
countries and, in the United States, is the most common cause of
death among women between 40 and 55 years of age (Forrest A P,
Screening and breast cancer incidence, J Natl Cancer Inst. 1990
Oct. 3; 82(19): 1525-6.). The incidence of breast cancer is
increasing, especially in older women, but the cause of this
increase is unknown. Malignant melanoma is another form of cancer
whose incidence is increasing at a frightening rate, at least six
fold in the United States since 1945, and is the single most deadly
of all skin diseases (Jemal et al., 2004).
[0006] One of the most devastating aspects of cancer is the
propensity of cells from malignant neoplasms to disseminate from
their primary site to distant organs and develop into metastases.
The early spread of viable tumor cells is considered a hallmark in
cancer progression. Despite advances in surgical treatment of
primary neoplasms and aggressive therapies, most cancer patients
die as a result of metastatic disease. Animal tests indicate that a
substantial frequency of circulating cancer cells from solid tumors
establish successful metastatic colonies (Fidler, 1993). Studies
have found that the detection of circulating metastatic tumor cells
and circulating tumor DNA in the blood of cancer patients
correlates with cancer progression. (Hoon D S, et al., Molecular
markers in blood as surrogate prognostic indicators of melanoma
recurrence, Cancer Res. 2000 Apr. 15; 60(8): 2253-7, and Taback B,
et al., Circulating DNA microsatellites: molecular determinants of
response to biochemotherapy in patients with metastatic melanoma,
J. Natl. Cancer Inst. 2004 Jan. 21; 96(2): 152-6, herein
incorporated in their entirety by reference).
[0007] Thus, the detection of occult cancer cells, DNA and tumor
markers in the circulation is important in assessing the level of
tumor progression and metastasis. Because subclinical metastasis
can remain dormant for many years, traditional surveillance
measures such as radiological monitoring with CT scans or MRI and
nodal biopsy may lack the sensitivity to detect early disease.
[0008] Notwithstanding the foregoing, there remains a need for
improved methods and devices for detecting biological components of
disease.
SUMMARY OF THE INVENTION
[0009] In one embodiment of the invention, a biological
surveillance probe for detecting disease is provided. The probe
comprises an elongate body having a proximal end and a distal end,
a binding surface attached to the elongate body, wherein the
binding surface has a microconfiguration for an increased surface
area, and at least one binding partner attached to the binding
surface to bind at least one complementary target. In some
embodiments, the binding surface is a microporous surface or has at
least one laser-drilled hole. In some embodiments, the binding
surface been configured by vapor deposition, physical vapor
deposition, chemical vapor deposition, sputtering, reactive
sputtering, sintering or vacuum deposition. The binding surface may
comprise a material selected from a group comprising a microporous
polymer, nanotube, metal, non-metal, ceramic or combination
thereof. The elongate body may be a catheter body or a stent
support. The binding surface may be a polymeric jacket. In some
embodiments, the probe may further comprise at least one optically
sensitive dye engaged to the binding surface, a fibrin-deposition
resistant component, at least one anti-thrombotic agent or
antimicrobial agent engaged to the binding surface. An atraumatic
tip may be attached to the distal end of the elongate body.
[0010] In another embodiment of the invention, a method for
collecting biological markers is provided. The method comprises the
steps of providing a collecting probe comprising a microconfigured
binding surface and at least one binding agent affixed to the
binding surface for binding a marker, positioning at least a
portion of the probe in an anatomical structure of a living
organism; maintaining the probe in a general position for a
specified period of time; and removing the probe from the living
organism. The method may further comprise the steps of binding at
least marker at a first point in time; and binding at least one
marker at a second point in time. The method may also comprise
binding at least one marker at a about first peak in marker
concentration and binding at least one marker at about a second
peak in marker concentration. The method may further comprise
analyzing the probe for markers bound to the binding agent. The
analyzing step may be performed ex vivo.
[0011] Several embodiments of the present invention provides these
advantages, along with others that will be further understood and
appreciated by reference to the written disclosure, figures, and
claims included herein.
BRIEF DESCRIPTION OF THE DRAWINGS
[0012] The structure and operation of the invention will be better
understood with the following detailed description of embodiments
of the invention, along with the accompanying illustrations, in
which:
[0013] FIG. 1 is a cross sectional view depicting one embodiment of
a probe capable of collecting biological components;
[0014] FIG. 2 represents an elevational view of another embodiment
of a probe with a guidewire lumen and side port;
[0015] FIGS. 3A and 3B are scanning electron micrographs depicting
various embodiments of the invention comprising porous
structures;
[0016] FIGS. 4A through 4D are micrographs illustrating various
configurations of the micro-porous tube of a probe;
[0017] FIGS. 5A and 5B are schematic side and front elevational
views of one embodiment of the probe comprising a proximal section
joined to a distal zone;
[0018] FIGS. 6A and 6B are schematic side and front elevational
views of another embodiment of the probe comprising a unitary body
design;
[0019] FIGS. 7A and 7B are schematic side and front elevational
views of one embodiment of a micro-porous probe with an atraumatic
tip. FIG. 7C is a longitudinal cross sectional schematic views of
one embodiment of a micro-porous probe in FIG. 7A.
[0020] FIG. 8A is a schematic of one embodiment of the probe
comprising a stent with a polymer fabric collecting surface; FIG.
8B is a cross sectional schematic view of the probe from FIG. 8A
within a blood vessel.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
[0021] The detection of occult cancer cells and other biological
markers has shown promise in the diagnosis and treatment of
disease. For example, the monitoring of patients' blood for
circulating tumor cells and other markers may prove advantageous in
detecting early tumor progression before metastasis to other organs
occurs. Circulating nucleic acids, tumor cells and proteins can be
detected in the blood (inclusive of plasma and serum), bone marrow,
cavity fluids and cerebrospinal fluid (CSF) of cancer patients
which may serve as risk stratification factors, markers for the
presence of clinical disease, predictors of subclinical and/or
minimal residual disease presence, determinants of treatment
response and disease progression, and prognosticators of patient
outcome. Other body fluids shown to have the above tumor cells,
protein markers, carbohydrate markers or nucleic acids include
urine, pleural fluids and peritoneal fluids (ascites). However,
assessment of these molecules/tumor cells or components thereof
requires a blood sample, which is collected at a single time-point
or at multiple time points by deliberate invasion of body tissue
(i.e. needle stick).
[0022] These methods are often limited by the intermittent and/or
low-level presence of cancer cells and markers in the blood.
Although new amplification and detection techniques, such as
immunochemistry, flow cytometry and reverse transcriptase
polymerase chain reaction, aid in the detection of early disease
markers, these techniques may fail to overcome sampling errors
inherent in the blood draws. Because of the constant circulating
nature of blood and the limited volume in a particular blood draw,
evaluating a single blood sample at one time-point may not
accurately represent the quantity and quality of circulating
nucleic acids, tumor cells, proteins or other tumor markers for
diagnosis, prognosis and monitoring of disease. Sampling error can
contribute to the frequent false-negative results found with
post-treatment cancer surveillance.
[0023] A major problem in detecting tumor cells and tumor markers
in blood is that they are not released at any particular time
point. Therefore, the probability of detecting the presence of
tumor cells or markers may vary or may be unpredictable. In
addition, it is known that for certain biological markers, blood
flow and release of these markers from tissues are diurnally
related and influenced by physical activity of an individual (i.e.,
climbing stairs). Circulating nucleic acids, tumor cells, proteins
etc as described above (here to fore termed circulating molecules
or cells or products will be referred as markers or CMC) may also
be released transiently into the blood stream by other
physiological events and external influences. Repetitive sampling
without repetitive invasive procedures would improve the accuracy
and sensitivity of detecting molecules circulating in blood.
[0024] CMCs appear to circulate in varying levels/concentrations
throughout a person's disease course as well as during a single day
and or in response to environmental manipulations such as treatment
with chemotherapy, hormonal therapy, immunotherapy and
radiotherapy, as well as with administration of medications. The
variations in the stability of these CMCs found in the blood or
other body fluids add to the inherent difficulties of an assay that
evaluates blood at a single time point. Serial assessment of blood
would increase the probability of identifying CMCs and therefore
improve their utility as prognostic, predictive and diagnostic
assays. However, serial assessments of patients' blood require
repeated patient needle sticks which are impractical, inconvenient
and uncomfortable to the patient.
[0025] A more practical and less intrusive approach would be to
introduce a collecting device, probe, biomaterial adhesive matrix,
chromatography affinity surface chip or probe, biochip, or particle
into the body that would come in direct contact with the blood or
body fluid over a period of time. This product can then be
assessed, in vivo or ex vivo, after an interval of elapsed time to
provide a more accurate evaluation of those CMCs. One embodiment of
the invention comprises a percutaneously inserted device that
resides indwelling in the bloodstream and is coated with or
contains a binding partner such as nucleotides (i.e.: oligos, LNAs
(locked nucleic acids), PNAs (peptide nucleic acids), cDNA, nucleic
acid probes, chromatographic affinity probes or fragments thereof
or their derivatives, complementary fragments or larger) antibodies
(i.e.: monoclonal, polyclonal, FAb fragments, etc) proteins or any
biological or synthetic material (i.e. biotin-avidin) that is
complementary to the CMC in question and that can be assessed in
vivo or ex vivo. The desired binding partner(s) are capable of
binding the corresponding target marker of interest in a sufficient
concentration and manner that permits retrieval of the probe after
an indwelling sample period of time for qualitative or quantitative
analysis of the marker.
[0026] The ex vivo concept is similar to a "dip stick" approach in
assessing a body fluid for a particular molecule. The in vivo
concept is a like an implantable physiological monitoring device. A
device and approach of such nature will provide a great improvement
over current methods of evaluating blood. The evaluation of the CMC
can be in the form of conventional monitoring using established in
vitro monitoring systems. For example, to detect circulating tumor
cells or circulating nucleic acids, one can use RealTime
quantitative PCR and oligonucleotide arrays. For detection of
proteins, one can use enzyme-linked immunosorbent assay (ELISA),
chromographic affinity assays, etc. For in vivo monitoring it can
be through electric or thermal related impulses or direct
imaging.
[0027] The detection time of the probe may be continuous, over
multiple intervals, or event-driven. Inactivating the detection
mechanism at times may conserve battery power. Reducing probe
binding surface exposure to the body at times may also reduce
fibrin deposition and other deleterious processes during periods of
low yield. For example, increased core body temperature or
increased serum potassium levels are correlated with cell lysis of
certain cancers and detection during of these events may enhance
the yield of interval collection and detection schemes. Other
event-based detection periods may include time period to assess a
patient's response to therapy through detection of components
related to cellular death. This allows measurement of a patient's
response, for example, to chemotherapy and/or radiation therapy,
which can then be optimized to for treatment effect or to minimize
side effects.
[0028] This device(s) can be inserted surgically, percutaneously or
intravenously into the blood stream, peritoneal cavity or bone
marrow such that continuous contact with circulating blood, and/or
body fluids is ensured. The product can then be collected for
analysis in a routine fashion or monitored. Several indwelling
devices are currently available that coexist with the patient that
in long-term contact with the blood and patients body fluids
without inducing an adverse reaction. These devices also do not
impair everyday patient activities of daily living. These devices
include but are not limited to centrally or peripherally inserted
intravenous catheters, pacemakers and their leads, automatic
internal converter defibrillators, hemodialysis catheters,
peritoneal catheters and prosthetic grafts.
[0029] One example of the proposed device is a coated catheter,
guidewire or filament, chip, biomaterial and/or matrix that can be
inserted through a centrally or peripherally place intravenous
catheter or implantable catheter/material into body fluids such as
peritoneal cavity, bone marrow, cerebrospinal fluid, etc. This
device can then dwell in continuous or intermittent contact with
the bloodstream and/or body fluids to improve yield of collecting
tumor cells, components thereof, circulating nucleic acids, and
proteins, or other items previously mentioned and or for prolonged
or continuous in vivo or ex vivo monitoring of marker presence or
activity. Monitoring time can vary in vivo from one to several days
to weeks or longer. This may provide valuable information on
markers of subclinical and/or minimal residual cancer presence and
determinants of treatment response and disease progression. Such
devices may also be used to monitor host states for other disease
progression patterns, including but not limited to infectious
processes and organ transplant rejection.
[0030] The invention described allows for continuous invasive
monitoring of CMCs. Through a percutaneous approach, a catheter can
be placed into the vasculature of a patient for continuous
monitoring of circulating tumor cells and/or their component.
Monitoring of CMCs may have diagnostic and prognostic value in
patient care as well as serve as an improved mechanism for
monitoring response to treatment. This indwelling catheter, for
example, may be impregnated with complementary substrate which can
include but are not limited to RNA, DNA, oligonucleotides,
proteins, carbohydrates, antibodies, LNAs, PNAs, probes, or any
component thereof and/or aforementioned in this application that
has affinity for binding to the CMC. When the desired substrate is
bound to the catheter, chip or any device mentioned in this context
contained therein, the substrate can be quantitated and evaluated
for information that can be conveyed to a self-embedded or external
detector. In addition, this catheter or device (including
nanoparticles, nanodevices, microfabricated devices, etc) and/or
with an associated chip or other device containing complementary
substrate to the source(s) for identification to which contains the
bound substrate of interest can be removed for ex vivo analysis
whereby the information obtained would provide both qualitative and
quantitative data.
[0031] In addition to enhancing the sensitivity of detecting cancer
and cancer recurrence, the invention allows assessment of
circulating tumor cells also would provide a rapid monitoring
system to determine if a specific therapy is effective.
[0032] In one embodiment of the invention, continuous
surveillance/monitoring of circulating nucleic acids (including
RNA, double stranded and single stranded DNA, chimeric RNA/DNA),
tumor cells, fetal cells, transplant allogeneic cells, transfected
cells, proteins, infectious disease nucleic acids, proteins,
carbohydrates (including glucoproteins, gangliosides and
phospholipids) in any complete components or fragment forms, is
performed to assess the presence and/or progression of disease.
These molecules will be detected in serum, plasma, whole blood,
bone marrow, CSF, lymphatic fluid, pleural or peritoneal fluids,
urine or other body fluids in patients with cancer, hyperplasia,
pregnancy (including prenatal diagnosis), patients with infectious
diseases symptomatic or asymptomatic with other medical conditions
such as infectious disease, autoimmune diseases, inflammatory
diseases, cardiovascular disease (including myocardial infarction,
unstable angina and congestive heart failure), neurovascular
diseases (e.g., ischemic events, stroke, anemia), pulmonary disease
(including acute respiratory distress syndromes, fibrosis,
pulmonary hypertension, emphysema, asthma, chronic obstructive
pulmonary disease), renal disease (infection, hypertension
nephropathies, nephritis, renal insufficiency and renal failure),
trauma patients, organ failure, critical care patients, and
transplant patients (including allogeneic and xenogeneic).
[0033] A. Binding Partners
[0034] The terms "binding partner" or "member of a binding pair"
refer to molecules that specifically bind other molecules (e.g., a
marker of interest) to form a binding complex such as
antibody-antigen, lectin-carbohydrate, nucleic acid-nucleic acid,
biotin-avidin, etc. In certain embodiments, the binding is
predominantly mediated by noncovalent (e.g. ionic, hydrophobic,
etc.) interactions.
[0035] One or more binding partners that specifically bind a target
marker to be detected are affixed in the binding zone on the probe
of the invention. The binding partner(s) used in this invention are
selected based upon the target marker(s) that are to be
identified/quantified. Thus, for example, where the target marker
is a nucleic acid the binding partner is preferably a nucleic acid
or a nucleic acid binding protein. Where the target marker is a
protein, the binding partner is preferably a receptor, a ligand, or
an antibody that specifically binds that protein. Where the target
marker is a sugar or glycoprotein, the binding partner is
preferably a lectin, and so forth. A device of the invention can
include several different types of binding partners, for example,
multiple nucleic acids of different sequence and/or nucleic acids
combined with proteins in the same device. The latter would
facilitate, e.g., simultaneous monitoring of gene expression at the
mRNA and protein levels. Other combinations of different types of
binding partners can be envisioned by those of skill in the art and
are within the scope of the invention. Furthermore, the binding
partner may be combined with an optically sensitive dye to
facilitate assessment of bound CMCs.
[0036] Methods of synthesizing or isolating such binding partners
are well known to those of skill in the art. For example, nucleic
acids for use as binding partners in this invention can be produced
or isolated according to any of a number of methods well known to
those of skill in the art. In one embodiment, the nucleic acid can
be an isolated naturally occurring nucleic acid (e.g., genomic
and/or mitochondrial DNA, cDNA, mRNA, etc.). Methods of isolating
naturally occurring nucleic acids are well known to those of skill
in the art (see, e.g., Sambrook et al. (1989) Molecular Cloning--A
Laboratory Manual (2nd Ed.), Vol. 1-3, Cold Spring Harbor
Laboratory, Cold Spring Harbor, N.Y.).
[0037] 1. Antibody-Based
[0038] Antibodies or antibody fragments for use as binding partners
can be produced by a number of methods well known to those of skill
in the art (see, e.g., Harlow & Lane (1988) Antibodies: A
Laboratory Manual, Cold Spring Harbor Laboratory, and Asai (1993)
Methods in Cell Biology Vol. 37. Antibodies in Cell Biology,
Academic Press, Inc. N.Y.). In one embodiment, antibodies are
produced by immunizing an animal (e.g., a rabbit) with an immunogen
containing the epitope to be detected. A number of immunogens may
be used to produce specifically reactive antibodies. Recombinant
proteins are the preferred immunogens for the production of the
corresponding antibodies. The antibodies may be monoclonal or
polyclonal. Naturally occurring protein may also be used either in
pure or impure form. Synthetic peptides are also suitable and can
be made using standard peptide synthesis chemistry (see, e.g.,
Barany and Merrifield, Solid-Phase Peptide Synthesis; pp. 3-284 in
The Peptides: Analysis, Synthesis, Biology. Vol. 2: Special Methods
in Peptide Synthesis, Part A., Merrifield et al. (1963) J. Am.
Chem. Soc., 85: 2149-2156, and Stewart et al. (1984) Solid Phase
Peptide Synthesis, 2nd ed. Pierce Chem. Co., Rockford, Ill.)
Preferably, human or humanized antibodies are used to prevent host
anti-xenogen antibody production. These antibodies may include
antibodies derived from hybridomas (tumor cells fused with
antibody-producing mammalian cells), humanized chimerics,
Epstein-Barr Virus transformed B-cells and transgenic
antibodies.
[0039] Methods for producing polyclonal antibodies are also well
known to those of skill in the art. In one embodiment, an immunogen
is mixed with an adjuvant and an animal is immunized. The animal's
immune response to the immunogen preparation is monitored by taking
test bleeds and determining the titer of reactivity to the
immunogen. When sufficient titers of antibody to the immunogen are
obtained, blood is collected from the animal and an antiserum is
prepared. If desired, the antiserum can be further fractionated to
enrich for antibodies having the desired reactivity. The animal may
be a monoclonal mouse, rat, rabbit, chicken or other animal known
in the art.
[0040] Monoclonal antibodies can be obtained by various techniques
familiar to those skilled in the art. In one embodiment, spleen
cells from an animal immunized with a desired antigen are
immortalized, commonly by fusion with a myeloma cell (See, Kohler
and Milstein (1976) Eur. J. Immunol. 6: 511-519). Alternative
methods of immortalization include transformation with Epstein Barr
Virus, oncogenes, or retroviruses, or other methods well known in
the art. Colonies arising from single immortalized cells are
screened for production of antibodies of the desired specificity
and affinity for the antigen, and yields of the monoclonal
antibodies produced by such cells can be enhanced by various
techniques, including injection into the peritoneal cavity of a
vertebrate host. Alternatively, DNA sequences encoding a monoclonal
antibody or a binding fragment thereof can be isolated by screening
a DNA library from human B cells according to the general protocol
outlined by Huse et al. (1989) Science, 246: 1275-1281. Such
sequences can then be expressed recombinantly.
[0041] In one embodiment of the invention, the technique comprises
attachment of an antibody or fragment of an antibody (referred to
as Ab) to a device that can allow capture of protein, circulating
tumor cells, DNA or RNA in the blood stream or body cavity. The
device will be coated with Ab in high density. The Ab may be
natural, recombinant (chimeric, Fab, scFv, etc.), or genetically
engineered. Preferably the Ab will be human to prevent anti-foreign
antibody responses (i.e. human antibody response to mouse
antibodies; HAMA). The device can be removed after insertion into
the blood stream to be monitored for biomarkers or cells it can
capture. The insertion device can be a catheter, array chip,
capture vessel, capture filter, and/or entrapment device. The
device can be inserted for 1, 2, 3, 4 . . . 24 hrs or days or
weeks. Monitoring of the captured biomarker or cells may be
assessed in vivo or ex vivo utilizing known techniques depending on
the biomarker or cell type. The biomarker or cells captured can be
assessed quantitatively or qualitatively. In another approach the
biomarker or cells captured will be monitored in vivo utilizing a
signaling indicator based on electrical, colorimetric or activation
signals.
[0042] In capturing cells the device would have specific Ab to
detect cell surface markers of cancer cells. Cancer cells have
distinct markers on their cell surface that distinguish them from
normal cells. This has been demonstrated by immunohistochemistry
(Racila E et al., Detection and characterization of carcinoma cells
in the blood, Proc Natl Acad Sci USA. 1998 Apr. 14; 95(8):
4589-94). These antibodies can be used to target epithelial origin
cells, tumor cells originated from specific tissues, non-epithelial
origin cells (i.e. melanoma). Circulating tumor cells are found in
the blood stream and body fluids of cancer patients (Hoon D S, et
al., "Detection of occult melanoma cells in blood with
multiple-marker polymerase chain reaction assay" J Clin One. 1995
August; 13(8); 2109-16, and Hoon D S, et al., "Molecular markers in
blood as surrogate prognostic indicators of melanoma recurrence"
Cancer Res. 2000 Apr. 15; 60(8): 2253-7.). Tumor cells spread to
distant organs via the blood stream, lymphatic ducts or body fluids
or body cavities. The spread of tumor cells can eventually lead to
tumor growth at distant sites from the original tumor, thus
producing metastasis. Growth of metatastatic tumor sites can lead
to death.
[0043] Detection of tumor cells can be used as an indicator of
disease spread, tumor aggressiveness, potential to spread to other
organs, and presence of disease in individuals who are otherwise
diagnosed as disease-free by conventional means. Detection of tumor
cells in vivo may be advantageous in some circumstances over ex
vivo detection. The approach will allow better capture of early
disease. One cannot predict disease spreading or volume through
single blood draw of a small amount of blood or body fluid. One
approach comprises catching tumor cells through a capturing system
placed in the blood stream or body fluid for a longer period of
time. This is may be advantageous when capturing occult circulating
metastatic or leukemic tumor cells. The cell surface marker can be
a protein, glycoprotein, glycolipid, peptide epitope,
conformational biological epitope or multiple disease or tumor
markers. The device may have more than one Ab attached to it to
improve sensitivity and capturing ability. The Ab may be to
multiple epitope sites of a single biomarker antigen. The tumor
cells captured will be dislodged when the device is removed and
assessed by the following ex vivo methods: immuno-histochemistry,
DNA, mRNA and/or proteomics.
[0044] The isolation of the cells may involve physical removal or
direct solvent removal specific to that biomarker's
physical-chemical properties. For example DNA and RNA from tumor
cells can be extracted directly from the tumor cells after
isolation. Isolation of DNA or RNA can be by solvents used for
nucleic acids. This can be accomplished directly or after the cells
have been dislodged. RNA and DNA can be detected by hybridization
to a specific probe, polymerase chain reaction (PCR) or related
monitoring approach. The assessment of nucleic acids from the tumor
cells can provide quantitative and qualitative analysis. Even if
non tumor cells are captured, the specificity of the analysis can
be optionally increased through a second tier analysis. Sensitivity
of the analysis can be further be enhanced through amplification of
the nucleic acids by PCR or related methods, incorporating specific
probes or detection systems ex vivo. Specificity and sensitivity ex
vivo for the specific nucleic marker can be approached using
current technologies. The DNA markers may include microsatellites,
mutations, translocations, insertions, amplifications, SNPs or
chromatin/DNA complexes. The RNA markers can include specific genes
in whole or part in the form of mRNA.
[0045] Protein, glycoprotein, or glycolipid analysis can be
detected by antibody, mass spectrophotometry, surface enhanced
laser desorption/ionization time-of-flight mass spectrometry
(SELDI-TOF MS), matrix-assisted laser desorption/ionisation-time of
flight mass spectrometry (MALDI-TOF MS), affinity assay,
chromatographic approach. The approach can be directly from the
device or removal of the biomarker by some solvent, physical method
or reagent to a vessel where it can be processed. The detection can
be in the form of an affinity matrix chip for the specific
biomarker type.
[0046] The Ab on the device can be a natural antibody produced by
human or some animal B cells in the form of polyclonal or
monoclonal antibody. The Ab can be a recombinant antibody that is
released from transfected mammalian or prokaryotic cells. The Ab
can be a fragment of an antibody such as scFV, FV or FAb fragment
that has specific recognition of the biomarker or cell epitope. The
Ab can be a genetically engineered Ab that has a specific
attachment moiety or detection ability.
[0047] The Ab on the device can be polyclonal or monoclonal
antibody to a specific epitope or multiple epitopes to a specific
biomarker or epitope. It can consist of multiple Ab to multiple
biomarkers. The latter will allow higher sensitivity and capturing
ability.
[0048] Ab can be attached to the device such as a catheter by
direct affinity attachment, chemical attachment, biological
attachment or electric charge. The Ab can be coated in a vessel,
tube or filter device, chip, filament, biopolymer matrix,
biological material, capsule matrix inserted into a patient.
[0049] The Ab-coated device can be inserted into the venous,
arterial or capillary beds of a patient. It can also be inserted
into a body cavity such as peritoneal, pleural, skin tissue, or
organ/tissue cavity created by surgical procedure.
[0050] 2. Protein-Based
[0051] In one embodiment, the binding partner can be a binding
protein. Suitable binding proteins include, but are not limited to,
receptors (e.g., cell surface receptors), receptor ligands (e.g.,
cytokines, growth factors, etc.), transcription factors and other
nucleic acid binding proteins, as well as members of binding pairs,
such as biotin-avidin.
[0052] Binding proteins useful in the invention can be isolated
from natural sources, mutagenized from isolated proteins, or
synthesized de novo. Means of isolating naturally occurring
proteins are well known to those of skill in the art. Such methods
include, but are not limited to, conventional protein purification
methods including ammonium sulfate precipitation, affinity
chromatography, column chromatography, gel electrophoresis and the
like (see, generally, R. Scopes, (1982) Protein Purification,
Springer-Verlag, N.Y.; Deutscher (1990) Methods in Enzymology Vol.
182: Guide to Protein Purification, Academic Press, Inc. N.Y.).
Where the protein binds a target reversibly, affinity columns
bearing the target can be used to affinity purify the protein.
Alternatively the protein can be recombinantly expressed with a
HIS-Tag and purified using Ni.sup.2+/NTA chromatography.
[0053] In another embodiment, the binding protein can be chemically
synthesized using standard chemical peptide synthesis techniques.
Where the desired subsequences are relatively short, the molecule
may be synthesized as a single contiguous polypeptide. Where larger
molecules are desired, subsequences can be synthesized separately
(in one or more units) and then fused by condensation of the amino
terminus of one molecule with the carboxyl terminus of the other
molecule thereby forming a peptide bond. This is typically
accomplished using the same chemistry (e.g., Fmoc, Tboc) used to
couple single amino acids in commercial peptide synthesizers.
[0054] The technique will involve detection of free circulating
proteins, peptides or protein complexes via an affinity matrix or
antibody or ligand (referred to as affinity substrate; AS) coated
to a device that can allow capture of proteins, peptides or
glycoproteins in the blood stream or body cavity. The device will
be coated with AS in high density. The device can be removed after
insertion into the blood stream to be monitored for biomarkers it
can capture. The insertion device can be a catheter, array chip,
capture vessel, capture filter, entrapment device. The device can
be inserted for 1, 2, 3, 4 . . . 24 hrs or days or weeks.
Monitoring of the captured biomarker or cells will be assessed ex
vivo utilizing known techniques depending on the biomarker type.
The biomarker captured can be assessed quantitatively or
qualitatively. In another approach the biomarker captured will be
monitored in vivo utilizing a signaling indicator based on
electrical, colorimetric or activation signals.
[0055] Protein and glycoprotein analysis can be detected ex vivo by
antibody, mass spectrophotometry, affinity assay, chromatographic
approach. The approach can be directly from the device or removal
of the biomarker by some solvent, physical method or reagent to a
vessel where it can be processed.
[0056] The antibody used on the device can be a natural antibody
produced by human or some animal B cells in the form of polyclonal
or monoclonal antibody. The antibody can be a recombinant antibody
that is released from transfected mammalian or prokaryotic cells.
The antibody can be a fragment of an antibody such as scFV, FV or
FAb fragment that has specific recognition of the biomarker or cell
epitope. The antibody can be a genetically engineered antibody that
has a specific attachment moiety or detection ability.
[0057] The AS can be in the form of affinity matrix material
specific or non specific for specific protein properties. The
former is preferable. For non-specific (not to a specific
biomarker) the AS can be based on charge to attract hydrophilic or
hydrophobic molecules. The antibody or ligand substrate on the
device can be towards a specific epitope or multiple epitopes to a
specific biomarker. It can consist of multiple AS to multiple
biomarkers. The latter will allow higher sensitivity and capturing
ability.
[0058] AS can be attached to the device such as a catheter by
methods including but not limited to direct affinity attachment,
chemical attachment, biological attachment or electric charge. The
AS can be coated in a vessel, tube or filter device, chip,
filament, biopolymer matrix, biological material, or capsule matrix
inserted into a patient.
[0059] The AS coated device can be inserted into the venous,
arterial or capillary beds of a patient. It can be inserted into a
body cavity such as peritoneal, pleural, skin tissue, or
organ/tissue cavity created by surgical procedure.
[0060] B. Affixation of Binding Partner to Probe
[0061] The desired binding partner(s) are affixed to the binding
zone on the probe in a sufficient concentration and manner to be
capable of binding the corresponding target marker of interest in a
manner that permits retrieval of the probe after an indwelling
sample period of time and qualitative or quantitative analysis of
the marker. The linkage between the binding partner and the
substrate surface on or attached to the probe is preferably
chemically stable under both in vivo and assay conditions. The
linkage may or may not produce significant non-specific binding of
target analyte(s) to the substrate. Many methods for immobilizing
molecules to a variety of substrates are known in the art. For
example, the binding partner can be covalently bound or
noncovalently attached through specific or nonspecific bonding.
[0062] If covalent bonding between a compound and the surface is
desired, the surface will usually be polyfunctional or be capable
of being polyfunctionalized. Functional groups that may be present
on the substrate surface and used for linking can include but are
not limited to carboxylic acids, aldehydes, amino groups, cyano
groups, ethylenic groups, hydroxyl groups, mercapto groups and the
like. The manner of covalently linking a wide variety of compounds
to various surfaces is well known and is amply illustrated in the
literature. See, for example, Ichiro Chibata (1978) Immobilized
Enzymes, Halsted Press, New York, and Cuatrecasas, (1970) J. Biol.
Chem. 245: 3059, herein incorporated by reference.
[0063] In addition to covalent bonding, various methods for
noncovalently bonding a binding partner can be used. Noncovalent
binding is typically, but not necessarily, nonspecific absorption
of a compound to the surface. Typically, the surface is blocked
with a second compound to prevent nonspecific binding of labeled
assay components. Alternatively, the surface is designed such that
it nonspecifically binds one component but does not significantly
bind another. For example, a surface bearing a lectin such as
concanavalin A or wheat germ agglutinin will bind a carbohydrate
containing compound but not an unglycosylated protein. Various
substrates for use in noncovalent attachment of assay components
are reviewed in U.S. Pat. Nos. 4,447,576 and 4,254,082, herein
incorporated by reference.
[0064] Where the binding partner is a nucleic acid or a
polypeptide, the molecule can be chemically synthesized in situ, if
desired. In situ nucleic acid or protein synthesis typically
involves standard chemical synthesis methods, substituting
photo-labile protecting groups for the usual protecting groups
(e.g., dimethoxy trityl group (DMT) used in nucleic acid
synthesis). Irradiation of the substrate surface at discrete
locations results in selective coupling of the monomer (e.g.,
nucleotide or amino acid) to the growing nucleic acid(s) or
polypeptide(s) at the irradiated site. Methods of light-directed
polymer synthesis are well known to those of skill in the art (see,
e.g., U.S. Pat. No. 5,143,854; PCT Publication Nos. WO 90/15070, WO
92/10092 and WO 93/09668; and Fodor et al. (1991) Science, 251,
767-77), herein incorporated by reference.
[0065] In one embodiment, the binding partner is immobilized to the
binding surface by the use of a linker (e.g. a homo- or
heterobifunctional linker). Linkers suitable for joining biological
binding partners are known in the art. For example, a nucleic acid
or protein molecule may be linked by any of a variety of linkers
including, but not limited to a peptide linker, a straight or
branched chain carbon chain linker, or by a heterocyclic carbon
linker. Heterobifunctional cross linking reagents such as active
esters of N-ethylmaleimide have been widely used (see, for example,
Lemer et al. (1981) Proc. Nat. Acad. Sci. USA, 78: 3403-3407 and
Kitagawa et al. (1976) J. Biochem., 79: 233-236, and Birch and
Lennox (1995) Chapter 4 in Monoclonal Antibodies: Principles and
Applications, Wiley-Liss, N.Y.), herein incorporated by
reference.
[0066] In one example, the binding partner is immobilized utilizing
a biotin/avidin interaction. In this embodiment, biotin or avidin
with a photolabile protecting group can be exposed to the binding
surface on the probe. Irradiation of the surface at a distinct
location results in coupling of the biotin or avidin to the surface
at that location. Then, a binding partner bearing an avidin or
biotin group, respectively, is contacted with the surface, forming
a biotin-avidin complex and is thus localized in the irradiated
site. To affix multiple different binding partners to different
locations, this process can be repeated at each binding partner
location.
[0067] Another potential photochemical binding approach is
described by Sigrist et al. (1992) Bio/Technology, 10: 1026-1028,
herein incorporated by reference. In this approach, the interaction
of ligands with organic or inorganic surfaces is mediated by
photoactivatable polymers with carbene generating
trifluoromethyl-aryl-diazirines that serve as linker molecules.
Light activation of aryl-diazirino functions at 350 nm yields
highly reactive carbenes, and covalent coupling is achieved by
simultaneous carbene insertion into both the ligand and the inert
surface. Thus, reactive functional groups are not required on
either the ligand or supporting material.
[0068] Binding partners can be affixed to any location on the
surface that contacts the sample during an assay according to the
invention. The binding surface on the probe may be varied
considerably in form, as may be desired based upon the binding
system requirements. For example, the binding surface may be the
externally facing surface of the probe. Alternatively or in
addition, as previously mentioned the probe may be tubular or may
comprise a porous structure to increase the surface area available
for the binding partner. A variety of open cell foam structures,
among others can significantly increase the effective surface area.
Any of a variety of other surface area enhancing design techniques
may also be used, such as providing a plurality of axially
extending fins, or a plurality of radially outwardly extending
circumferential rings in the binding area of the probe.
[0069] C. Probe Configurations
[0070] 1. Catheter-Based Probes
[0071] Referring to FIG. 1, there is disclosed a CMC or marker
binding and retrieval probe 10 in accordance with one aspect of the
present invention. Although the probe 10 will be described
primarily in terms of an insert to be temporarily placed down an
existing access port or sheath into the cardiovascular system, for
retrieving a marker from blood, the present inventors contemplate
broader applicability as will be apparent to those of skill in the
art in view of the disclosure herein. Existing access ports or
sheaths include but are not limited to Hickman catheters, Portacath
catheters, peripherally inserted central catheter (PICC) lines,
femoral, jugular, or subclavian central venous lines, radial
arterial catheters and peripheral venous lines. Furthermore,
additional procedures, such as transseptal puncture and
transjugular intrahepatic puncture, may be used to access other
body sites such as the arterial chambers of the heart or the portal
vein, respectively.
[0072] For example, the probe may be adapted for direct access to a
target site, without the use of a distinct tubular access catheter.
In general, whether used with an access sheath or as a stand alone
device, the dimensions of the probe can be optimized by persons of
skill in the art in view of the present disclosure to suit any of a
wide variety of target sites. For example, the probe of the present
invention can be used to obtain samples from large and small
arteries and veins throughout the cardiovascular system, as well as
other lumens, potential spaces, hollow organs and surgically
created pathways. Marker (tumor and/or non-tumor) collection may be
accomplished in blood vessels, body lumens or cavities, such as the
lymphatic system, esophagus, trachea, urethra, ureters, fallopian
tubes, intestines, colon, biliary ducts, spinal canal and any other
locations accessible by a flexible or rigid probe which may contain
a specific binding partner of diagnostic value. The probe 10 may
also be adapted for direct advance through solid tissue, such as
soft tissue or through bone, for site specific monitoring of a
binding partner of interest.
[0073] The probe 10 generally comprises an elongate body 16
extending between a proximal end 12 and a distal functional end 14.
The length of the body 16 depends upon the desired access site and
the desired placement site for the distal end 14. For example,
lengths in the area of from about 1 cm to about 20 or 30 cm may be
useful in applications that require the catheter to be advanced
down a relatively short tubular access sheath. Longer lengths may
be used as desired, such as on the order of from about 120 cm to
about 140 cm for use in percutaneous access at the femoral artery
for placement of the distal end 14 in the vicinity of the coronary
artery. Intracranial applications may call for a different catheter
shaft length depending upon the vascular access site, as will be
apparent to those of skill in the art.
[0074] Many markers of interest, however, may be equally
retrievable at any point throughout the cardiovascular system, in
which case the probe 10 may be adapted to advance down any
convenient access port that may have been placed for other
diagnostic or therapeutic use. Devices in accordance with the
present invention may also be adapted for exposure to blood by
coupling to any of a variety of ports on extracorporeal circulation
systems as will be apparent to those of skill in the art in view of
the disclosure herein.
[0075] In the illustrated embodiment, the body 16 is divided into
at least a proximal section 33 and a distal binding zone 34. In
general, distal binding zone 34 is adapted to carry a binding
partner for the marker of interest, as will be discussed below, and
may or may not be otherwise structurally distinct from the proximal
section 33.
[0076] At least the proximal section 33 of body 16 may be produced
in accordance with any of a variety of known techniques for
manufacturing catheter bodies, depending upon the desired clinical
performance. For example, the body 16 may be formed by extrusion of
any of a variety of appropriate biocompatible polymeric materials.
Known materials for this application include high density
polyethylene, polytetrafluoroethylene, nylons, PEEK, PEBAX and a
variety of others such as those disclosed in U.S. Pat. No.
5,499,973 to Saab, the disclosure of which is incorporated in its
entirety herein by reference. Alternatively, at least a proximal
portion or all of the length of body 16 may comprise a spring coil,
solid walled hypodermic needle tubing, or braided reinforced wall,
as is understood in the catheter and guidewire arts. Whether metal
or polymeric or a hybrid, the body 16 may be hollow or solid
depending upon the nature of the binding system and other desired
capabilities.
[0077] In one cardiovascular example, the body 16 is provided with
an approximately circular cross-sectional configuration having an
external diameter within the range of from about 0.025 inches to
about 0.100 inches. In accordance with one embodiment of the
invention, the body 16 has an average external diameter of about
0.042 inches (4.2 f) throughout most of its length. Alternatively,
generally rectangular, oval or triangular cross-sectional
configurations can also be used, as well as other noncircular
configurations, depending upon the method of manufacture, desired
surface area, flexibility, access pathway and other design
considerations that may be relevant for a particular
application.
[0078] Dimensions outside of the ranges identified above may also
be used, provided that the functional consequences of the
dimensions are acceptable for the intended purpose of the catheter.
For example, the lower limit of the cross section for any portion
of body 16 in a given application will be a function of the number
of fluid or other functional lumens, if any, contained in the
probe, together with the desired surface area to be available for
the binding partner, as will be discussed.
[0079] Probe body 16 should also have sufficient structural
integrity (e.g., column strength or "pushability") to permit the
probe to be advanced to a desired target site without buckling or
undesirable bending.
[0080] The proximal end 12 of the probe 10 may be provided with a
grip 46 such as a polymeric cap 48 which may be molded or otherwise
secured to the proximal end 12 of the body 16. Preferably, the cap
is provided with a complementary surface structure to allow a
removable connection between the cap and the proximal end of the IV
catheter or other device through which the probe 10 will achieve
contact with blood or other body fluid. Removable attachment may be
accomplished by using any of a wide variety of clips, twist
fasteners such as Luer connectors, interlocking snapfit connectors,
or friction fit connectors as will be appreciated by those of skill
in the art in view of the disclosure herein.
[0081] The axial length of the probe 10 is preferably precisely
calibrated to match the particular access catheter with which it is
to be used, to provide a reproducible length of the binding zone to
be exposed to the sample of interest.
[0082] Referring to FIG. 2, there is disclosed an alternative
implementation of the probe of the present invention. The proximal
end 12 of probe 10 is provided with a manifold 18 having one or
more access ports as is known in the art. Manifold 18 may be
provided with a guidewire port 20 in an embodiment where
over-the-wire navigation of the probe may be desired. An infusion
port 22 may be provided with or without the guidewire port. The
infusion port is in fluid communication with the binding zone
through an infusion lumen. This allows periodic or continuous
infusion of saline, heparin or other media to prevent "clogging" or
coating of the binding zone over time, by natural clotting or other
processes which may interfere with the efficacy of the binding
chemistry. Additional access ports may be provided as needed,
depending upon the desired capabilities of the catheter. Manifold
18 may be injection molded from medical grade plastics or formed in
accordance with other techniques known in the art.
[0083] The distal end 14 of the probe 10 may be provided with an
atraumatic distal tip 25 which may include a guidewire exit port 26
in a guidewire lumen embodiment as is known in the art. A
radiopaque marker (not illustrated) may be provided on the probe
body 16 in the case of relatively long probes to facilitate
positioning of the probe as is known in the art. Suitable marker
bands can be produced from a variety of materials, including
platinum, gold, and tungsten/rhenium alloy.
[0084] The distal zone of the probe is provided with a binding
zone, having a binding partner for binding with a marker of
interest. As used herein, the term marker refers to any CMC
discussed above, as well as any other cell, cell fragment, protein,
peptide, glycoprotein, lipid, glycolipid, proteolipid, or other
molecular or biological material that is uniquely expressed (e.g.
as a cell surface or secreted protein) by diseased cells, or is
expressed at a statistically significant, measurably increased or
decreased level by diseased cells, or in association with a disease
state of interest (e.g. a protein expressed by an infectious agent
associated with disease), or is expressed at a statistically
significant, measurably increased or decreased level by diseased
cells compared to normal cells, or which is expressed by
non-diseased cells in association with disease (e.g. in response to
the presence of diseased cells or substances produced therefrom).
Disease markers can also include specific DNA or RNA sequences
marking a deleterious genetic change, conformational change
compared to baseline or normal, or an alteration in patterns or
levels of gene expression significantly associated with disease.
Disease markers include breast cancer markers.
[0085] The term cancer marker refers to a subset of disease
markers, namely any protein, peptide, glycoprotein (including but
not limited to mucins, mucoid and amyloid glycoproteins), lipid,
glycolipid, proteolipid, or other molecular or biological material
that is uniquely expressed (e.g. as a cell surface or secreted
protein) by cancerous cells, or is expressed at a statistically
significant, measurably increased or decreased level by cancerous
cells compared to normal cells, or which is expressed by
non-cancerous cells in association with cancer (e.g. in response to
the presence of cancerous cells or substances produced therefrom).
Cancer markers can also include specific DNA or RNA sequences
marking a deleterious genetic change, conformational change, or an
alteration in patterns or levels of gene expression significantly
associated with cancer.
[0086] a. Binding Zone Surface Area
[0087] The binding zone may be configured with an increased surface
area to provide an increased number of binding sites on the probe.
The surface area may be increased by providing an increased
longitudinal length, increased diameter or cross-section through at
least a portion of the distal zone. In addition, or alternatively,
at least a portion of the distal zone may comprise a porous
material and/or microstructure to increase the surface area.
Non-limiting examples of porous materials include porous polymers,
ePTFE, PTFE, polyurethane, silicone, foam, or a ceramic with a
porous surface (e.g., titanium nitride, titanium carbide, carbon,
and silicon carbide). Various techniques for depositing material on
the probe surface to provide a porous structure may also be used
and include ion beam deposition, sintering, sputtering, ion
implantation, laser surface alloying, electroplating, physical or
chemical vapor deposition, chemical or physical etching, grit
blasting, plasma and thermal spray coating. Other materials that
can be applied to the probe surface include iridium oxide, graphite
and platinum black. The surface area may be increased through
microstructures on the binding zone surface, formed from processes
including but not limited to mechanical roughening of the probe
surface, laser drilling or metal sintering onto the probe. The
probe may also be manufactured using microporous tubing, porous
fabric and polymers, carbon fiber bundles, and nanotubes. The
surface area of the binding zone may be configured by one skilled
in the art depending upon the expected release pattern, degradation
and metabolization pathways and binding kinetics of the CMCs of
interest. FIGS. 3A and 3B represent scanning electron micrographs
(SEM) of various porous configurations that provide an increased
surface area for the probe. FIG. 3A depicts one embodiment of the
invention comprising a microporous zone formed by vapor deposition.
FIG. 3B depicts another embodiment of the invention formed with
sintered metal beads. One skilled in the art will understand that a
variety of metals may by used for a sintered porous surface,
including but not limited to platinum, platinum/iridium and other
platinum group metals or alloys thererof, titanium, titanium alloys
and 316L stainless steel. In one embodiment, the sintered metal
zone has an average pore size of about 5 microns to about 150
microns to allow particle access into the microporous structure. In
other embodiments, an average pore size of about 5 microns to about
100 microns may be used. In one example, a sintered metal porour
zone has an average pore size of about 10 microns to about 50
microns. Microporous structures will typically have a porosity
between about 10% to about 80%. In some embodiments, the porous
layer has a porosity of about 10% to about 60%, and preferably
about 40%. Other binding zone structures that increase the surface
area are shown in FIGS. 4A through 4D. FIG. 4A is a photograph of a
porous fabric. FIG. 4B depicts a porous polymer. FIG. 4C depicts
laser drilled holes in a polymer surface and FIG. 4D depicts a
nanotube microstructure for providing an increased surface
area.
[0088] b. Distal Tip Configurations
[0089] FIGS. 5A and 5B depict one implementation of the invention,
where the body 16 of the probe 10 comprises a proximal section 33
and a distal zone 34 attached through a joint area 50. In one
embodiment, the proximal section 33 has an average outer diameter
of about 0.5 mm to about 2 mm, but average outer diameters from
about 1 mm to about 30 mm may also be used, depending on the
desired location and positioning procedure. The proximal section 33
may be made through extrusion or molding using any of a variety of
flexible biocompatible polymers including but not limited to PEBAX,
polyurethane (Q747), PE, PTFE, nylon, silicone rubber, or
combinations thereof. The polymer typically have a hardness within
the range of about 80A to about 75D, but polymers within other
hardness ranges may also be used. In another embodiment, the
polymer has a hardness of about 10D to about 80D. In one
embodiment, the proximal section may have a length of about 20 mm
to about 300 mm. In other embodiments, the proximal section may
have a length of about 20 cm to about 40 cm, or about 80 cm to
about 140 cm, depending on the distance from the insertion point to
the target location. The joint area 50 may have any of a variety of
configurations for attaching the proximal section 33 and the distal
zone 34, including but not limited a male/female configuration or
any other mechanical or friction fit known in the art. The proximal
section 33 and distal zone 34 may be joined in any of a variety of
ways, including but not limited to adhesive bonding with medical
grade epoxy, polyurethane adhesives, fast setting glue, UV cure
adhesives, solvent fusing or heat fusing. A metallic core may be
included in proximal section 33 and/or distal zone 34 to provide
sufficient column strength or pushability.
[0090] FIGS. 6A and 6B illustrate another embodiment of the
invention where the proximal section 33 and the distal zone 34
comprise the same material and therefore, a joint area is not
required. If an increased surface area on the distal zone 34 is
desired, laser drilling and other methods previously mentioned may
be used to alter the surface area.
[0091] In some embodiments of the invention, an atraumatic tip is
provided at the distal end of the probe to reduce potential damage
to the probe and the surrounding tissue during insertion. FIGS. 7A
through 7C represent one embodiment of the probe comprising an
atraumatic tip. Referring to FIG. 7A, the distal zone 34 of the
probe 10 comprises a micro-porous segment 52 joined at a joint area
50 to a soft tip 54. The soft tip comprises a distally rounded
structure comprising a material such as PEBAX, polyurethane (Q747),
silicone rubber, PTFE, nylon, or other biocompatible polymer having
a hardness within the rarige of about 80A to about 75D. The soft or
atraumatic tip 54 has a length of about 2 mm to about 6 mm and is
joined at its proximal end 56 to a porous segment 52 at a joint
area 50 using an adhesive such as a polyurethane adhesive, an
epoxy, fast setting glue, UV cure adhesive or other adhesives known
in the art. The porous segment has a length of about 1 mm to about
10 mm and an average diameter of about 0.5 mm to about 2 mm or
more. As illustrated in FIG. 7C, the porous segment 52 may comprise
a ring or tubular structure, but other structures with a core may
also be used. The porous ring is joined at its proximal end 58 to
the proximal section 33 of the probe at another joint area 50 using
an adhesive or other joining process.
[0092] At least a portion of the porous segment 52 comprises a
binding zone for interacting with one or more CMCs. The binding
zone of the distal zone may have a diameter of about 0.5 mm to
about 2 mm. In another embodiment, the binding zone has an average
diameter of about 1 mm to about 5 mm or more. In one embodiment,
the binding zone has a length of about 1 mm to about 10 mm. In
another embodiment, the binding zone has a length of about 5 mm to
about 30 mm or more. The binding zone may comprise a porous
material and/or porous microstructure as previously mentioned, such
as a sintered metal, a porous ceramic, a sputtered or vacuum
deposited metal or ceramic, a porous polymer or a laser-drilled
material. Further detail of the binding zone is provided below.
[0093] The body 16 of the probe 10 may optionally comprise at least
one lumen generally along the length of the body 16 for passing the
probe over a guidewire. The lumen may pass from the proximal
section 33 to the distal zone 34 and exit the distal end 14 of the
probe 10. Alternately, the lumen may terminate prior to the distal
end 14 of probe 10 at the exterior surface of the proximal section
33 or distal zone 34, similar to a rapid-exchange catheter.
[0094] 2. Detachable Probes
[0095] In another embodiment of the invention, depicted in FIGS. 8A
and 8B, the probe 60 is configured so that it is capable of
implantation within the body and does not require a permanent
proximal attachment for manipulation and/or retrieval of the probe
60. A detachable or implantable probe 60 may be beneficial where
detection of a CMC requires prolonged exposure to the body, but the
probe 60 is not limited to this particular use. By detaching from
its delivery tool, contact between the probe and the external
surface of the body and the probe surface area within the body may
be reduced. This may decrease the risk of thrombogenicity and/or
infection created by the presence of the probe 60. Those with
cancer or a history of cancer or other disease may be predisposed
to clot formation and infection and may benefit from additional
measures to reduce such risks.
[0096] In one embodiment, the probe comprises a binding zone and an
engagement interface for reversibly engaging a delivery/retrieval
tool. The binding zone comprises at least one site for interacting
with one or more CMC. The configuration of the binding zone is
described in further detail below. The engagement interface
comprises a mechanical or friction interface capable of forming a
mechanical or friction fit with a delivery/retrieval tool to
facilitate implantation and removal of the probe. The engagement
interface may be further configured to orient the probe with
respect the delivery/retrieval tool to facilitate positioning and
removal of the probe through narrow openings such as a blood
vessel. The probe may further comprise a support for maintaining
the configuration of the binding zone and resisting deformation of
the binding zone. The support may be useful where the binding zone
comprises a thin or pliable surface. The probe may optionally
comprise an anchor system for maintaining the position of the probe
in a general or particular location.
[0097] In one embodiment of the invention, the probe 60 comprises a
stent support 64 attached to a binding zone jacket 62. The
stent-support comprises 64 a first end 66, a second end 68, a lumen
70 between the first end and second end, and may be configured
similar to a vascular stent with a mesh-like or zig-zag structure,
as shown in FIGS. 8A and 8B. The stent support 64 may be
self-expanding or balloon-expandable. One skilled in the art will
understand that any of a variety of stent structures,
configurations and materials may be used, including but not limited
to nitinol, 316L stainless steel, platinum or platinum/iridium. The
stent support 64 may be dimensioned for placement in any of a
variety of locations, including but not limited to cardiovascular
system, a peripheral vein or artery, biliary system, urinary tract,
gastrointestinal tract and other lumens or body cavities, natural
or artificial. In one embodiment, the stent support has an average
diameter of about 0.5 mm to about 2 mm. In another embodiment, the
stent support has an average diameter of about 1 mm to about 8 mm.
The stent support may have a length of about 5 mm to about 60 mm.
In another embodiment, the stent support has a length of about 10
mm to about 30 mm.
[0098] A binding zone jacket 62 is attached to at least a portion
of the stent support 64. The jacket 62 may surround a portion of
the stent support 64 or may be fixed within the lumen 70 of the
stent support 64. One or more jackets may be attached to the stent
64. The jacket surface may comprise a biocompatible porous material
or porous microstructure to increase the potential binding surface
area available. Biocompatible porous materials include but are not
limited to PEBAX, polyurethane (Q747), silicone rubber, PTFE and
nylon. The configuration of the binding zone jacket is described in
further detail below. Alternatively, the binding zone may be
directly bonded onto the surface of the stent configuration and a
jacket is not required.
[0099] Stent retrieval is known in the art and may be performed in
several ways. Representative patents include but are not limited to
U.S. Pat. No. 6,569,181 to Burns and U.S. Pat. No. 6,187,016 to
Hedges et al., herein incorporated in their entirety by reference.
The stent support may further comprise one or more engagement
elements to facilitate retrieval of the stent from the body by a
retrieval tool.
[0100] In addition to affixing a binding partner to the binding
zone, other molecules or components may be bound to the binding
zone to facilitate or support the function of the binding zone. In
one embodiment, heparin is bound to the binding zone and possibly
other portions of the probe to resist thrombus formation that may
increasingly affect the function of the binding partners with
extended exposure time to the body. Heparin coating of medical
devices is well known in the art, as described by Hsu et al. in
U.S. Pat. No. 5,417,969, herein incorporated in its entirety by
reference. In another embodiment, a streptokinase coating is
provided to resist clot formation (Niku S D et al., Isolation of
lymphocytes from clotted blood, J Immunol Methods. 1987 Dec. 4;
105(1): 9-14, herein incorporated by reference). Other materials
that may be bonded to the binding zone or probe surface include but
are not limited to hydrogels or other lubricious coatings, as
described by Hostettler et al. in U.S. Pat. No. 5,919,570, and
antimicrobial agents, as described by Raad and Sherertz in U.S.
Pat. No. 5,688,516, herein incorporated in their entirety by
reference. An antimicrobial component may reduce the risk of probe
colonization by infectious bacterial and fungal organisms for a
probe placed into a body for an extended period of time. Such
antimicrobial agents may include but are not limited to
aminoglycoside, amphotericin B, ampicillin, carbenicillin,
cefazolin, cephalosporin, chloramphenicol, clindamycin,
erythromycin, gentamicin, griseofulvin, kanamycin, methicillin,
nafcillin, novobiocin, penicillin, polymyxin, rifampin,
streptomycin, sulfamethoxazole, sulfonamide, tetracycline,
trimethoprim, and vancomycin.
[0101] The probe may further comprise an optional elution zone
capable of retaining and releasing one or more substances such as
drug compounds, reagents or other substances. In one embodiment,
the elution zone releases a substance that enhances release of a
CMC from the body. In another embodiment, the elution zone releases
a substance that facilitates detection of a CMC, including but not
limited to Ab labeled fluorescent dyes. In still another
embodiment, the elution zone releases a substance capable of
reducing a body's immune response to an antigenic element on the
probe. In another embodiment, the elution zone is capable of
releasing one or more treatment agents for reducing fibrin
deposition onto the binding zone and other portions of the probe.
Fibrin deposition may decrease or affect the binding of CMCs to
their binding partners into the binding zone. Agents that may be
released from the elution zone include but are not limited to
dexamethasone, paclitaxel, unfractionated heparin, low-molecular
weight heparin, enoxaprin, synthetic polysaccharides, ticlopinin,
dipyridamole, clopidogrel, fondaparinux, streptokinase, urokinase,
r-urokinase, r-prourokinase, rt-PA, APSAC, TNK-rt-PA, reteplase,
alteplase, monteplase, lanoplase, pamiteplase, staphylokinase,
abciximab, tirofiban, orbofiban, xemilofiban, sibrafiban,
roxifiban, bivalirudin, and pentoxifylline.
[0102] Alternatively, a chip-based detection system may be used.
For example, DNA/oligonucleotide chip detection involves attachment
or incorporation of a chip into a device to be inserted into the
blood stream or body cavity. The assessment of nucleic acids bound
to the chip may be performed in vivo directly through electronic or
chemical signaling or ex vivo by a detection device. For DNA
analysis this will include microsatellite analysis for loss of
heterozygosity (LOH) or by single nucleotide polymorphism (SNP).
Other genomic DNA markers can include mutations, amplifications and
translocations. The analysis may involve specific or multiple sites
of the chromosomal or mitochondrial DNA from tumor cells. RNA
analysis will involve assessment of mRNA of transcripts of specific
genes related to the tumor cells. The mRNA transcript may be of the
whole or part of the full transcript or a truncated derivative of
the transcript. The procedure may also include chromatin and DNA
complexes (histone proteins) related to specific genomic regions of
tumor cells. The procedure may encompass assessing acetylation and
deacetylation of chromatin regions of specific genomic regions,
methylated or non-methylated. The procedure may encompass assessing
methylated or non-methylated regions of the genomic regions such as
promoter related-regions of tumor-related genes. The chip may be
inserted for 30 min, 1, 2, 3 . . . 24 hr and removed for assessment
or assessed directly.
[0103] D. Insertion and Placement of Collection Probe
[0104] The collection probe may be inserted in a variety of ways
and to variety of locations within the body. In some situations,
the probe may be inserted during a cancer surgery where access to
sentinel sites of disease recurrence is readily accessible. For
instance, following a mastectomy and axillary node dissection for
breast cancer, a collecting probe may be implanted during the same
procedure into the lymphatic ducts draining the breast. Such as
site may provide earlier detection of recurring disease and may
also increase the yield from such surveillance. Similarly,
placement of the collection probe surgically may also allow or
subcutaneous implantation into a large vein while the patient is
still under anesthesia, thereby decreasing the risk of infecting
the device compared to percutaneous insertion.
[0105] The device may also be configured for percutaneous
insertion. Some embodiments of the device allow insertion of the
probe into existing long-term access sites such as a Hickman
catheter, Portacath, or a peripherally inserted central catheter
(PICC) line or variants thereof. Similarly, the probe may also be
configured for insertion through central venous catheters inserted
into the femoral or jugular vein, or large-bore IV access site. For
example, a Portacath is an implantable venous access device that is
frequently used in cancer patients to provide long-term vascular
access for chemotherapy. A detection probe placed into a Portacath
or a Portacath variant may serve a dual function of treating the
cancer and provide the ability to monitor treatment effect.
[0106] In use, a probe having at least one binding partner is
provided. The probe is advanced to a site where a binding zone on
the probe will be exposed to a carrier such as blood which may
periodically contain a marker of interest. The probe is left in
place for an evaluation period, to allow the marker to become bound
to the binding partner. The probe is thereafter withdrawn, and
evaluated to determine the presence of any marker carried by the
binding zone.
[0107] In one application, the probe is advanced through an access
tube to position the binding zone at an intralumenal site within an
artery or vein. The binding zone is left at the site for an
evaluation period of generally at least about one hour, in come
applications at least about four or six hours, and for certain
markers at least about 12 hours or 24 hours or more. This allows
collection of at least a first quantity of a target marker from a
first release of marker into the blood, and in certain applications
at least also a second quantity of the target marker from a second
release of marker into the blood, the first and second releases
separated in time from each other. The first and second quantities
of the target marker may be collected on the same probe.
Alternatively, during the evaluation period, a first probe may be
withdrawn from the site and replaced by at least a second probe,
which carries the same or a second binding partner.
[0108] The device may be inserted through any of a variety of
access methods known to interventional radiology, cardiology,
gastroenterology and other medical and veterinary disciplines.
These procedures may include but are not limited to endoscopic
retrograde cholangiopancreatography (ERCP) for placement into the
biliary tree or pancreas, transseptal puncture for placement into
the arterial portion of the cardiovascular system, lumbar puncture
into the cerebrospinal fluid, and cystoscopy for placement into the
urinary tract.
[0109] E. Ex Vivo Probe Assessment
[0110] The capture of nucleic acids from an in vivo device can be
monitored ex vivo using standard qualitative and quantitative
molecular assays. The assays can directly measure the nucleic acids
or amplify them to measure them. The assays can be probe-,
sequence- or affinity ligand-based. The assessment of DNA/RNA in
body fluids ex vivo is known and currently available. These include
but are not limited to gel electrophoresis, real time quantitative
polymerase chain reaction (PCR), probe based chromatographic
assays. For DNA analysis, this will include microsatellite analysis
for loss of heterozygosity or by single nucleotide polymorphism
(SNP). Other DNA markers can include mutations, amplifications,
insertions and translocations. This may be specific or multiple
sites of the DNA from tumor cells. RNA analysis will involve
assessment of mRNA of transcripts of specific genes related to the
tumor cells. The mRNA transcript may be of the whole or part of the
full transcript or a truncated derivative of the transcript. The
procedure may also include chromatin and DNA complexes related to
specific genomic regions of tumor cells. The procedure may also
include assessment of acetylated and de-acetylated or modified
regions of the chromatin and histones surrounding a specific gene.
The procedure may also include assessment of methylation or
demethylation of gene promoter regions.
[0111] Assessment of antibody or protein-based markers is currently
available and may include but is not limited to affinity binding
assays, mass spectroscopy, and ELISA. Similarly, of carbohydrate
markers is also known and may include affinity or ligand-bsed
capture assays and mass spectroscopy. One skilled in the art can
select one or more assays based upon the particular marker or
markers of interest.
[0112] One embodiment of the invention comprises a percutaneously
insertable device affixed with antibodies that recognize
tumor-related cell surface proteins/glycoproteins (i.e.: cMet,
HER2/neu, beta-Human chorionic gonadotropin (HCG), MUC-1, etc) or
glycolipids (gangliosides GM2, GD2). The antibodies can capture and
bind the circulating tumor cells in the blood or body fluid. Single
or multiple antibodies to a specific cell surface marker or
multiple markers may be used. The capture device or catheter with
the bound tumor cells can be removed and subjected to standard ex
vivo isolation methods known in the art for RNA, DNA, carbohydrate
and protein isolation and purification. The isolation of these cell
products is one approach to identify their specificity. Another
approach is to isolate the cells and assess them as whole cells.
These approaches are advantageous in providing a unique in vivo
enrichment method for the collection of circulating tumor cells and
their subcomponents, such as DNA, RNA and proteins, for further
evaluation and assessment.
[0113] In some embodiments, the cells can be removed physically,
biochemically or eluted off the device by competitive reagents to
the antibody. Preferably, once eluted, the cells can undergo
respective component isolation. In other embodiments, the cells are
analyzed while still attached to the device. In one example, cells
can be processed, purified and quantitated for specific nucleic
acids such as RNA and DNA by methods known in the art. To assess
the amount of nucleic acids, one can perform qualitative and/or
quantitative analysis for specific RNA and DNA markers that are
tumor-related. These markers may be different from the antibody
specific markers that are used to capture the cells. The antibody
used to capture markers may also be used.
[0114] In one embodiment, cell capture with antibody to c-Met is
performed and then assessment for cMet mRNA expression is performed
qualitatively or quantitatively by realtime PCR. PCR provides
amplification of the target mRNA marker and allows for detection
through many available approaches including but not limited to as
gel electrophoresis, realtime PCR thermocyclers, etc.
[0115] In one embodiment, tumor mRNA markers for assessment can
include markers most prevalent in the type of cancer being
assessed, but less prevalent markers may also be used. For example,
in melanoma one could assess for MART-1 mRNA. For breast cancer one
can assess mammoglobin. Quantitative marker detection may be used
to rule out false positives. This provides another layer of
specificity to the detection scheme. Also, to increase the
sensitivity of the detection scheme, multiple markers can be used
to assess for isolated tumor cells. One can also assess for
specific DNA markers such as mutations, loss of heterozygosity,
amplification, translocation, etc. Specific genetic changes may be
related to specific cancers or groups of cancers. Specific genetic
changes can be used in combination with multiple marker detection
approaches. Some examples include detection of BRAF mutation at
V600 for melanoma, methylation of RASSF1a promoter site, or LOH at
9p21. The use of specific nucleic markers can be used to determine
specific types of cancers, level of disease malignancy, disease
aggressiveness, prognostic and predictive values and other
information.
[0116] In one approach, proteins are isolated and purified by
direct isolation. These proteins can be assessed by ELISA for
specific tumor markers, Western Blot approaches, mass spectrometry,
protein arrays, ProteinChips, antibody based assays, affinity
protein based assays, etc in a quantitative and qualitative manner.
The approaches can be used for glycoproteins and other carbohydrate
markers. The use of specific protein/glycoprotein/carbohydrate
markers can be used to determine specific types of cancers, level
of disease malignancy, disease aggressiveness, prognostic and
predictive values and other information.
[0117] Another approach is to elute the cells. Cells bound to the
catheter can be evaluated using conventional histopathologic and
immunocytochemical staining methods that characterize the collected
cells of interest. These cells can be evaluated directly on the
catheter or, in one embodiment, the cells are isolated from the
catheter using standard methods to disrupt tumor cell complementary
antibody binding through current methods of mechanical separation
(such as scraping and/or washings with saline, buffered solutions,
or media). In another embodiment, chemical dissociation techniques
are used and include washing the catheter/antibody/tumor cell
complex with pH buffered solutions (such as PBS with EDTA or salts
that disrupt antibody binding to cells but not destroy the cells,
etc.), thus allowing the cells to be collected intact after
separation from the catheter/antibody complex and assessed by
conventional methods such as immunostaining procedures. In still
another embodiment, cells may also be released by disrupting the
antibody-cell complex from the device. After isolation, the cells
can be immunostained with specific antibodies against tumor cell
surface markers or intracellular markers. The assessment of tumor
cells may be performed by conventional immunopathology for tumor
cell diagnosis, but other approaches are known in the art,
including but no limited to immunostained cells by FACs analysis.
In these approaches, multiple antibodies can be used for detection
to improve sensitivity and specificity for specific cells. Also,
some approaches allow detection of the number of cells detected for
quantitation of disease level. Cells can be also assessed by
conventional or non-conventional stains and dyes that are not
antibody-based. Still another approach is in situ hybridization
with nucleic acids or derivative molecules that are complimentary.
The above approaches for detection of eluted cells, intact or not
intact, for specific components (protein, nucleic acids, etc) can
be approached quantitatively or qualitatively. The approaches can
be by individual or combination of methods.
[0118] While this invention has been particularly shown and
described with references to embodiments thereof, it will be
understood by those skilled in the art that various changes in form
and details may be made therein without departing from the scope of
the invention. For all of the embodiments described above, the
steps of the methods need not be performed sequentially.
* * * * *